{
    "clinical_study": {
        "@rank": "26592", 
        "arm_group": [
            {
                "arm_group_label": "Single-agent PD-0332991", 
                "arm_group_type": "Experimental", 
                "description": "Phase 1 Part 1"
            }, 
            {
                "arm_group_label": "PD-0332991 in combination with letrozole", 
                "arm_group_type": "Experimental", 
                "description": "Phase 1 Part 2"
            }, 
            {
                "arm_group_label": "PD-0332991 with letrozole", 
                "arm_group_type": "Experimental", 
                "description": "Phase 2"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is comprised of two portions: a Phase 1 portion and a Phase 2 portion.  The Phase\n      1 portion is a single-country, non-randomized, open label, clinical trial which will\n      evaluate the safety, tolerability, preliminary efficacy, and PK profile of PD-0332991 as a\n      single agent in Japanese patients with advanced solid tumors, and PD-0332991 in combination\n      with letrozole in the first-line treatment of Japanese patients with ER(+) HER2(-) ABC. The\n      Phase 2 portion is a single-country, non-randomized, open-label, single-cohort, multi-center\n      clinical trial to evaluate the efficacy and safety of PD-0332991 in combination with\n      letrozole for the first-line treatment of postmenopausal Japanese patients with ER(+)\n      HER2(-) ABC."
        }, 
        "brief_title": "A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neoplasms", 
            "Breast Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Phase 1\n\n          -  In Part 1, advanced solid tumor (except SCLC or retinoblastoma) proven histologically\n             or cytologically at original diagnosis, that is refractory to standard therapy or for\n             whom no standard of care therapy is available.\n\n          -  In Part 2 and Phase 2, post menopausal women with proven diagnosis of ER-positive,\n             HER2-negative adenocarcinoma of the breast with evidence of locoregionally recurrent\n             or metastatic disease (including bone only disease) not amenable to resection or\n             radiation therapy with curative intent and for whom chemotherapy is not clinically\n             indicated.\n\n          -  Adequate blood cell counts, kidney function and liver function and and Eastern\n             Cooperative Oncology Group [ECOG] score of 0 or 1.\n\n          -  Resolved acute effects of any prior therapy to baseline severity or Grade \u22641\n\n        Phase 2\n\n          -  Adult women (\u2265 20 years of age) with proven diagnosis of adenocarcinoma of the breast\n             with evidence of locoregionally recurrent or metastatic disease not amenable to\n             resection or radiation therapy with curative intent and for whom chemotherapy is not\n             clinically indicated.\n\n          -  Documentation of histologically or cytologically confirmed diagnosis of ER(+) breast\n             cancer based on local laboratory results.\n\n          -  Adequate blood cell counts, kidney function and liver function and and Eastern\n             Cooperative Oncology Group [ECOG] score of 0 to 2.\n\n        Exclusion Criteria:\n\n        Phase 1\n\n          -  Active uncontrolled or symptomatic CNS metastases.\n\n          -  Uncontrolled infection, unstable or sever intercurrent medical condition, or current\n             drug or alcohol abuse\n\n          -  Active or unstable cardiac disease or history of heart attack within 6 months\n\n        Phase 2\n\n          -  HER2 positive tumor based on local laboratory results utilizing one of the sponsor\n             approved assays.\n\n          -  Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or\n             leptomeningeal disease.\n\n          -  Prior neoadjuvant or adjuvant treatment with a non steroidal aromatase inhibitor (ie,\n             anastrozole or letrozole) with disease recurrence while on or within 12 months of\n             completing treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01684215", 
            "org_study_id": "A5481010"
        }, 
        "intervention": [
            {
                "arm_group_label": "Single-agent PD-0332991", 
                "description": "PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach.  Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.", 
                "intervention_name": "PD-0332991", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PD-0332991 in combination with letrozole", 
                "description": "PD-0332991, 125 mg, will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach.  PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.", 
                "intervention_name": "PD-0332991", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PD-0332991 in combination with letrozole", 
                "description": "Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.", 
                "intervention_name": "letrozole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PD-0332991 with letrozole", 
                "description": "PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment.  PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.", 
                "intervention_name": "PD-0332991", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PD-0332991 with letrozole", 
                "description": "Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.", 
                "intervention_name": "letrozole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Letrozole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1/2", 
            "PD-0332991", 
            "palbociclib", 
            "Cyclin Dependent Kinase 4/6 inhibitor", 
            "Japanese", 
            "solid tumors", 
            "breast cancer", 
            "A5481010"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481010&StudyName=A%20Study%20Of%20Oral%20Palbociclib%20%28PD-0332991%29%2C%20A%20CDK4/6%20Inhibitor%2C%20As%20Single%20Agent%20In%20Japanese%20Patients%20With%20Advanced%20Solid%20Tumors%20Or"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa", 
                        "country": "Japan", 
                        "state": "Chiba"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-Ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1/2 Study Of The Efficacy, Safety, And Pharmacokinetics Of Oral PD-0332991, A Cyclin-Dependent Kinase 4 And 6 (CDK4/6) Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number of participants with Dose-limiting toxicities (DLT)", 
                "measure": "Number of participants with Dose-limiting toxicities (DLT)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to 28 days"
            }, 
            {
                "description": "PFS at 12 months after first dose of study treatment", 
                "measure": "Investigator-assessed 1-year Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 52 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01684215"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.", 
                "measure": "Area under the Concentration-Time Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose"
            }, 
            {
                "description": "Maximum Observed Plasma Concentration (Cmax)", 
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 4, 6, 8, 12, 24 hours post-dose"
            }, 
            {
                "description": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 4, 6, 8, 12, 24 hours post-dose"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 4, 6, 8, 12, 24 hours post-dose"
            }, 
            {
                "description": "Minimum Observed Plasma Trough Concentration (Cmin)", 
                "measure": "Minimum Observed Plasma Trough Concentration (Cmin)", 
                "safety_issue": "No", 
                "time_frame": "Day 15 of Cycle 1 and Cycle 2"
            }, 
            {
                "description": "OR is defined as a complete response (CR) or partial response (PR) according to RECIST v.1.1. recorded from randomization until disease progression or death due to any cause.", 
                "measure": "Objective Response (OR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 2.5 months"
            }, 
            {
                "description": "DC is defined as complete response (CR), partial response (PR), or stable disease (SD) =24 weeks according to the RECIST version 1.1 recorded in the time period between randomization and disease progression or death to any cause.", 
                "measure": "Disease Control (DC)", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 2.5 years"
            }, 
            {
                "description": "Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cancer.", 
                "measure": "Duration of Response (DR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 2.5 months"
            }, 
            {
                "description": "Median time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.", 
                "measure": "Progression-Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to measured progressive disease"
            }, 
            {
                "description": "Overall survival was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to date of death from any cause"
            }, 
            {
                "description": "FACT-B is used for assessment of health-related quality of life (QoL) in participants with breast cancer.", 
                "measure": "Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B)", 
                "safety_issue": "No", 
                "time_frame": "Cycles 1, 2 and 3 and then every other cycle thereafter starting with Cycle 5"
            }, 
            {
                "description": "Tumor tissue biomarkers will be analyzed to investigate possible associations with resistance/sensitivity to treatment with study drugs. Biomarkers that will be analyzed will be selected based on their known relevance to mechanisms involved in cell cycle regulation.", 
                "measure": "Tumor tissue biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Baseline and End of the study"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}